{"drugs":["Alvesco","Ciclesonide","Omnaris","Zetonna"],"mono":{"0":{"id":"928653-s-0","title":"Generic Names","mono":"Ciclesonide"},"1":{"id":"928653-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928653-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Allergic rhinitis:<\/b> (Omnaris(R)) 2 sprays (50 mcg\/spray) in each nostril once daily; MAX total daily dose of 2 sprays in each nostril (200 mcg\/day)<\/li><li><b>Allergic rhinitis:<\/b> (Zetonna(TM)) 1 actuation (37 mcg\/actuation) in each nostril once daily; MAX total daily dose of 1 actuation in each nostril (74 mcg\/day)<\/li><li><b>Asthma:<\/b> (Alvesco(R)) previous bronchodilators use, initial, 80 mcg ORAL INHALATION twice daily; MAX, 160 mcg INHALATION twice daily<\/li><li><b>Asthma:<\/b> (Alvesco(R)) previous inhaled corticosteroid use, 80 mcg ORAL INHALATION twice daily; MAX, 320 mcg twice daily<\/li><li><b>Asthma:<\/b> (Alvesco(R)) previous oral corticosteroid use, 320 mcg ORAL INHALATION twice daily; MAX, 320 mcg ORAL INHALATION twice daily; with gradual reduction of oral corticosteroid (prednisone no faster than 2.5 mg\/day on a weekly basis) after at least 1 week of ciclesonide therapy<\/li><\/ul>"},"1":{"id":"928653-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>(Omnaris(R)) effectiveness for the treatment of perennial rhinitis in children under 12 years of age has not been established and effectiveness for the treatment of seasonal rhinitis in children under 6 years of age has not been established; (Zetonna(TM)) safety and efficacy in children under 12 years of age have not been established<\/li><li><b>Allergic rhinitis:<\/b> (Omnaris(R), 6 years and older; seasonal allergic rhinitis) 2 sprays (50 mcg\/spray) in each nostril once daily; max total daily dose of 2 sprays in each nostril (200 mcg\/day)<\/li><li><b>Allergic rhinitis:<\/b> (Omnaris(R), 12 years and older; perennial allergic rhinitis) initial, 2 sprays (50 mcg\/spray) in each nostril once daily; max total daily dose of 2 sprays in each nostril (200 mcg\/day)<\/li><li><b>Allergic rhinitis:<\/b> (Zetonna(TM), 12 years and older; seasonal or perennial allergic rhinitis) 1 actuation (37 mcg\/actuation) in each nostril once daily; MAX total daily dose of 1 actuation in each nostril (74 mcg\/day)<\/li><li><b>Asthma:<\/b> (Alvesco(R)) 12 years and older, previous bronchodilators use, 80 mcg ORAL INHALATION twice daily; MAX, 160 mcg INHALATION twice daily<\/li><li><b>Asthma:<\/b> (Alvesco(R)) 12 years and older, previous inhaled corticosteroid use, initial, 80 mcg ORAL INHALATION twice daily; MAX, 320 mcg twice daily<\/li><li><b>Asthma:<\/b> (Alvesco(R)) 12 years and older, previous oral corticosteroid use, initial, 320 mcg ORAL INHALATION twice daily; MAX, 320 mcg ORAL INHALATION twice daily; with gradual reduction of oral corticosteroid (prednisone no faster than 2.5 mg\/day on a weekly basis) after at least 1 week of ciclesonide therapy<\/li><\/ul>"},"3":{"id":"928653-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Allergic rhinitis<\/li><li>Asthma<\/li><\/ul>"}}},"3":{"id":"928653-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928653-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to ciclesonide or any other component of the product<\/li><li>primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive intervention (oral inhalation)<\/li><\/ul>"},{"id":"928653-s-3-10","title":"Precautions","mono":"<ul><li>adrenal insufficiency and hypercorticism, sometimes severe, has been reported; increased risk when switching from systemic therapy or with higher doses and prolonged duration of use; carefully observe patients during periods of stress for inadequate adrenal response; supplemental oral corticosteroids may be necessary<\/li><li>angioedema with involvement of the lips, tongue and pharynx has been reported<\/li><li>bone mineral density loss; associated with orally-inhaled corticosteroid use, especially with prolonged immobilization, family history of osteoporosis, and chronic use of drugs that reduce bone mass (eg, anticonvulsants and oral corticosteroids); monitoring recommended (oral inhalation)<\/li><li>bronchospasm may occur following dosing for asthma; treat immediately with a fast-acting inhaled bronchodilator; discontinuation and switch to an alternative therapy may be necessary (oral inhalation)<\/li><li>Candida albicans infection may occur; monitoring recommended; discontinuation of therapy may be required<\/li><li>cataracts, glaucoma, or increased intraocular pressure; new onset or worsening may occur; monitoring recommended<\/li><li>epistaxis, nasal ulceration, nasal septal perforation may occur; avoid direct contact with nasal septum; discontinuation of therapy may be required (nasal spray)<\/li><li>immunosuppression may result in more susceptibility to serious infections and communicable diseases; use caution or avoid use in patients with untreated systemic fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex<\/li><li>nasal septum ulcers, nasal trauma, or recent nasal surgery; use not recommended until healed (nasal spray)<\/li><li>pediatric patients; may reduce growth velocity; routine monitoring recommended<\/li><li>tuberculosis, active or quiescent; use caution or avoid use<\/li><li>unvaccinated or patients without a history of chickenpox or measles; increased risk of severe or even fatal course of illness; if exposed, immune globulin and\/or antiviral therapy may be needed<\/li><li>to report suspected adverse reactions, contact the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"928653-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928653-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928653-s-4","title":"Drug Interactions","sub":{"1":{"id":"928653-s-4-14","title":"Major","mono":"<ul><li>Itraconazole (probable)<\/li><li>Pixantrone (theoretical)<\/li><\/ul>"}}},"5":{"id":"928653-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Musculoskeletal:<\/b>Arthralgia (oral inhalation, 0.9% to 3.5%), Backache (oral inhalation, 0.6% to 3.1%)<\/li><li><b>Neurologic:<\/b>Headache (intranasal, up to 3.1%; oral inhalation, 4.9% to 11%)<\/li><li><b>Otic:<\/b>Otalgia (intranasal, 2.2%)<\/li><li><b>Respiratory:<\/b>Epistaxis (intranasal, 2.9% to 11.4%), Nasal congestion (oral inhalation, 1.8% to 5.5%), Nasopharyngitis (intranasal, 3.7%; oral inhalation, 7% to 10.5%), Pain in throat (oral inhalation, 2.4% to 4.7%), Sinusitis (oral inhalation, 3.1% to 5.5%), Upper respiratory infection (intranasal, at least 2%; oral inhalation, 4.1% to 8.7%)<\/li><li><b>Other:<\/b>Pain, In extremity (oral inhalation, 0.3% to 3.1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Endocrine metabolic:<\/b>Adrenal insufficiency<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (rare)<\/li><li><b>Ophthalmic:<\/b>Cataract, Glaucoma, Raised intraocular pressure<\/li><li><b>Respiratory:<\/b>Bronchospasm, Exacerbation of asthma (6%)<\/li><\/ul>"},"6":{"id":"928653-s-6","title":"Drug Name Info","sub":{"0":{"id":"928653-s-6-17","title":"US Trade Names","mono":"<ul><li>Omnaris<\/li><li>Alvesco<\/li><li>Zetonna<\/li><\/ul>"},"2":{"id":"928653-s-6-19","title":"Class","mono":"<ul><li>Adrenal Glucocorticoid<\/li><li>Anti-Inflammatory<\/li><\/ul>"},"3":{"id":"928653-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928653-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928653-s-7","title":"Mechanism Of Action","mono":"The precise mechanism of action of corticosteroids in asthma and allergic rhinitis is unknown. Corticosteroids have been shown to have a wide range of effects on multiple cell types (mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic inflammation. Ciclesonide is a pro-drug that is enzymatically hydrolyzed to des-ciclesonide, the pharmacologically active metabolite.<br\/>"},"8":{"id":"928653-s-8","title":"Pharmacokinetics","sub":[{"id":"928653-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral inhalation: 1.04 hours<\/li><li>Bioavailability, Oral: less than 1%<\/li><li>Effect of food: not established<\/li><\/ul>"},{"id":"928653-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: 99% or greater<\/li><li>Vd, ciclesonide (prodrug): 2.9 L\/kg<\/li><li>Vd, des-ciclesonide (active metabolite): 12.1 L\/kg<\/li><\/ul>"},{"id":"928653-s-8-25","title":"Metabolism","mono":"<ul><li>Nasal mucosa: hydrolysis to active metabolite, des-ciclesonide, via esterases<\/li><li>Lung: hydrolysis to active metabolite, des-ciclesonide, via esterases<\/li><li>Liver: predominantly CYP3A4<\/li><li>Metabolite: des-ciclesonide: active<\/li><\/ul>"},{"id":"928653-s-8-26","title":"Excretion","mono":"<ul><li>Renal clearance:  20% or less as des-ciclesonide (active metabolite)<\/li><li>Fecal: 66% as des-ciclesonide (active metabolite)<\/li><li>Total body clearance: 152 L\/hr (ciclesonide); 228 L\/hr (des-ciclesonide)<\/li><\/ul>"},{"id":"928653-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Ciclesonide: 0.71 hours<\/li><li>Des-ciclesonide: 6 to 7 hours<\/li><\/ul>"}]},"9":{"id":"928653-s-9","title":"Administration","mono":"<ul><li><b>Inhalation, oral<\/b><br\/>Alvesco(R) prime the inhaler by actuating 3 times before the first use or when the inhaler has not been used for more than 10 consecutive days; no need to shake inhaler before use<br\/><\/li><li><b>Nasal<\/b><br\/><ul><li>(Omnaris(R)) shake and prime the pump by actuating 8 times before use<\/li><li>(Omnaris(R)) if not used for 4 consecutive days, gently shake and re-prime with one spray or until a fine mist appears<\/li><li>(Zetonna(TM)) prime the pump by actuating 3 times before initial use<\/li><li>(Zetonna(TM)) re-prime the pump with 3 actuations if not used for 10 consecutive days<\/li><li>(Zetonna(TM)) reassemble device and test with 1 test-spray if canister and actuator become separated<\/li><\/ul><\/li><\/ul>"},"10":{"id":"928653-s-10","title":"Monitoring","mono":"<ul><li>asthma: reduction in symptoms and improved pulmonary function tests, such as FEV1, are evidence of efficacy (oral inhalation)<\/li><li>seasonal or perennial allergic rhinitis: reduction in symptoms of are evidence of efficacy (nasal inhalation)<\/li><li>(oral inhalation) bone mineral density in patients with major risk factors for decreased bone mineral content.<\/li><li>cataracts and glaucoma; routinely, especially in patients with a change in vision and\/or a history of cataracts, glaucoma, or increased intraocular pressure<\/li><li>linear growth velocity in pediatric patients; routinely<\/li><li>signs and symptoms of candida infections of mouth, pharynx and nose<\/li><\/ul>"},"11":{"id":"928653-s-11","title":"How Supplied","mono":"<ul><li><b>Alvesco<\/b><br\/>Inhalation Aerosol Liquid: 80 MCG\/Actuation, 160 MCG\/Actuation<br\/><\/li><li><b>Omnaris<\/b><br\/>Nasal Spray: 50 MCG\/Actuation<br\/><\/li><li><b>Zetonna<\/b><br\/>Nasal Aerosol Liquid: 37 MCG\/Actuation<br\/><\/li><\/ul>"},"13":{"id":"928653-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient that the inhalation aerosol is not indicated for acute asthma attacks or status asthmaticus.<\/li><li>Instruct patient to avoid exposure to chickenpox and measles. If exposure occurs, notify healthcare professional immediately.<\/li><li>Drug may cause headache, nasal discomfort, or nose bleed.<\/li><li>The oral inhalation aerosol may also cause nasopharyngitis, sinusitis, pharyngolaryngeal pain, upper respiratory infection, nasal congestion, or arthralgia.<\/li><li>Advise patient to immediately report changes in vision.<\/li><li>Advise patient using oral inhalation that symptomatic improvement may not be seen for 4 weeks or longer.<\/li><li>Instruct patient to report signs\/symptoms of hypothalamic-pituitary-adrenal (HPA) axis suppression (fatigue, depression, anxiety, hyperglycemia, muscle weakness, immunosuppression symptoms). Patients on long-term therapy may be at increased risk for these effects.<\/li><li>Patient should also report signs\/symptoms of infection, including fungal infection of the mouth and pharynx.<\/li><li>Caregivers of pediatric patients should monitor for and report decreased growth rate.<\/li><li>Instruct patients using the oral inhaler to use it exactly as directed and to rinse mouth with water after each use to prevent oral infections.<\/li><li>Advise patient against sudden discontinuation of drug.<\/li><li>Instruct patient on proper administration technique. Avoid direct contact with nasal septum or eyes.<\/li><\/ul>"}}}